Cingulate Announces Q3 Net Loss of $7.3 Million Compared to $4.1 Million Last Year

Written by Emily J. Thompson, Senior Investment Analyst

CING-3.21%

Updated: Nov 13 2025

0mins

Financial Status: As of September 30, 2025, Cingulate reported approximately $6.1 million in cash and cash equivalents, reflecting a decrease from December 31, 2024.
Capital Needs: The company anticipates needing to raise about $7.0 million in additional capital to support commercialization efforts leading up to the May 31, 2026 PDUFA date for CTx-1301.
Working Capital: Cingulate's working capital stood at approximately $1.6 million as of September 30, 2025, down from $7.7 million at the end of 2024.
Future Projections: The company expects its current cash reserves will meet its capital needs into the second quarter of 2026 under the existing business plan.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy CING?" and start using high-conviction signals backed by rigorous historical data.

Sign up today to access powerful investing tools and make smarter, data-driven decisions.

CING

$5.72+Infinity%1D

Analyst Views on CING

Wall Street analysts forecast CING stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CING is 27.33 USD with a low forecast of 8.00 USD and a high forecast of 58.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Analyst Rating

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 5.910

Low

8.00

Averages

27.33

High

58.00

Current: 5.910

Low

8.00

Averages

27.33

High

58.00

Roth Capital

Boobalan Pachaiyappan

Buy

downgrade

$17 -> $16

2025-11-18

Reason

Roth Capital

Boobalan Pachaiyappan

Price Target

$17 -> $16

AI Analysis

2025-11-18

downgrade

Buy

Reason

Roth Capital analyst Boobalan Pachaiyappan lowered the firm's price target on Cingulate to $16 from $17 and keeps a Buy rating on the shares, with the firm noting it caught up with Cingulate management to discuss Q3 results. At a high level, the company is ratcheting up its CTx-1301 U.S. pre-commercialization efforts through its Indegene partnership, the analyst tells investors in a research note. The firm expects CTx-1301 approval by May 31, 2026.

Roth Capital

NULL

to

Buy

upgrade

$10 -> $17

2025-10-14

Reason

Roth Capital

Price Target

$10 -> $17

2025-10-14

upgrade

NULL

to

Buy

Reason

Roth Capital raised the firm's price target on Cingulate to $17 from $10 and keeps a Buy rating on the shares. The FDA's acceptance of Cingulate's NDA package suggests that the agency is likely comfortable with the safety-efficacy characteristics of CTx-1301 in ADHD patients, the analyst tells investors in a research note. The lack of Ad Comm, a PDUFA date that is at least 2 months ahead of Roth's expectations, a potential broad label to all ADHD patients, and importantly, the stellar approval record of all ADHD stimulants, are all good reasons to buy Cingulate stock, the firm added.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CING

Unlock Now

About CING

Cingulate Inc. is a biopharmaceutical company. The Company is focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The Company is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). The Company’s CTx-1301 and CTx-1302 are being developed for the treatment of ADHD in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+). In addition, the Company has a third product to treat anxiety, CTx-2103, in a formulation stage. Its CTx-1301, CTx-1302 and CTx-2103 drug candidates contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

GET FREE REAL TIME NOTIFICATIONS

Stock Monitor for CING?

Get Started Free

FREE STOCK RECOMMENDATIONS DAILY

Stock Bullish Tomorrow

Get Started Free

70% BACKTESTED ACCURACY!

Should I Buy CING?

Get Started Free

Top News

Cingulate Announces Q3 Net Loss of $7.3 Million Compared to $4.1 Million Last Year

Trade with 70% Backtested Accuracy

Analyst Views on CING

About CING

About the author

Top News

Oil Firms Cautious on Venezuela Investment Push

GM Reports $7.1 Billion Charge Amid EV Shift

Stock Market Wraps 2025 with Double-Digit Gains

Novo Nordisk's Weight-Loss Pill Approval: Key Impacts

Related Articles

Intel Faces Crucial Turning Point in Chip Manufacturing

AGNC Investment Corp. Sees Turnaround in 2025 Performance

Biotech Stocks Surge: Coherus Up 9.09% in After-Hours Trading

Roth Capital Reaffirms Buy Rating on Cingulate, Reduces Price Target to $16

Sigh Up to Get Intellectia Insights

How did the company's recent strategic decisions impact its latest financial performance?

Can you explain the factors behind the recent changes in the company's stock price?

What are the expected impacts of current market trends on the company's future growth?

Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?

How does the company's performance compare to its main competitors in the same sector?

People Also Watch